Get the Weekly Intelligence Brief — top committee picks every Sunday.
BSX · NYSE · STOCK

Boston Scientific (BSX) Stock Analysis

Healthcare Updated August 25, 2026
$49.39
52W $42.20 – $109.50
62/100
$72.85B
19.8
0.57
AI Committee Verdict
Buy
62/100
Conviction: Contested · 60% agreement · 5 analysts
+11.7%
-1.3%
8.93:1
Contested

Is BSX Bullish or Bearish?

Bullish. Innellis AI committee rates Boston Scientific (BSX) Buy with a composite score of 62/100 , based on 5 analysts with 60% agreement. Last updated August 25, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +13.17 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -6.83 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — 5 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 17.9% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • News sentiment is positive (+0.33 across 25 articles, 14d) — News
Bear Case
  • Bollinger bandwidth of 17.9% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 25, 2026
Overall Committee Score
62/100
Agreement
60%
Analysts
5
Conviction
Contested
Sector Rank
Top 23%
of 192 Healthcare peers
Growth Analyst bullish
82 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 17.9% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
68 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 25 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3063.01)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 59.8 to 61.8.

Analyst-level changes:
  • Growth Analyst: score 79->82 (+4).
  • Value Analyst abstained (was neutral at 53).

Comparing 2026-08-24 to 2026-08-25 (1 day apart).

Technical Analysis

RSI (14)
43.9
Neutral
MACD Histogram
-0.147
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Lh Ll
Support
$48.37
Resistance
$54.74
Bollinger %B
0.45
Inside Bands
Price vs Moving Averages
EMA 9
$50.19 Below
EMA 21
$49.22 Above
EMA 50
$48.96 Above
EMA 200
$64.53 Below

Fundamental Analysis

Valuation
86
Growth
78
Profitability
78
Financial Health
68
Cash Flow
70
Valuation
P/E Ratio 19.8×
P/B Ratio 2.90×
PEG Ratio 0.43
Dividend Yield 0.00%
52W High $109.50
52W Low $42.20
Quality & Growth
ROE 1190.9%
ROA 660.8%
Gross Margin 7115.6%
Operating Margin 2146.1%
Revenue Growth YoY
Debt / Equity 0.51
AI Fundamental Assessment
P/E ratio of 19.8 (inexpensive relative to a 15-40x range); Price-to-book of 2.9x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 11.9%; Return on assets of 6.6%; Net margin of 17.5%; Gross margin of 71.2%; Current ratio of 1.24 (tight short-term liquidity); Debt-to-equity of 0.51; Free cash flow per share is positive (2.45); Most recent quarter beat estimates by 2.9%; 5 consecutive earnings beats; EPS growth accelerating (+0.0% -> +7.5% QoQ); Average YoY EPS growth of 14.7%; Analyst estimates rising over recent quarters
Get the Full BSX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime